-
Christine Lagarde: unifying ECB chief in turbulent times
-
ECB President Christine Lagarde to step down in February 2027
-
Rybakina secures year-end top rank with Tokyo win
-
A year on, Tanzanians mourn election massacres in 'state of terror'
-
Rains bring relief to Indonesian city weary of fire haze
-
Israel piles pressure on Arab parties as Netanyahu seeks government
-
Osaka vows to return stronger after Tokyo exit
-
'Call of Duty' slammed for using real Seoul crowd crush footage
-
Hello Kitty firm apologises, scraps Japan TV tie-up after China anger
-
TotalEnergies profit hits record on high oil prices
-
Taiwan says Pakistan briefly closed airspace to Taiwanese flights
-
Key of seethe: I.Coast row with Sahel juntas spills into concert halls
-
'My blood was spilled here': a year on, Tanzania unable to mourn election violence
-
Romanian writer Cartarescu hails books as balm in turmoil
-
Afghanistan opium poppy cultivation surges despite Taliban govt ban: UN
-
Mbappe, Real Madrid and La Liga face long road to redemption in China
-
No World Series miracle for weary Rays
-
North Korea fires 'around a dozen' ballistic missiles into East Sea
-
Miami Heat earn first win of NBA season with Antetokounmpo
-
Brewers catcher Contreras named World Series MVP
-
Brewers beat Rays 4-1 to capture first World Series title
-
Asian stock markets fluctuate after mixed tech results
-
Philippine island fights rising seas with nature, not concrete
-
Samsung logs record quarterly profits despite investor AI jitters
-
Bangladesh presses India before Ganges water treaty expires
-
Miami stumble to draw against Cincinnati despite Suarez strike
-
Trump accuses Alaska Democrats of fraud over same-name scandal
-
Bangladesh scrambling as Ganges water treaty to expire
-
Spain mourns after latest train tragedy kills 68
-
England in peril with Rugby League World Cup semi spots at stake
-
Trump's border: quiet, but few people are happy
-
Antonelli ready to rewrite the Formula One record books in Mexico
-
Australian defence chief says China military buildup creating 'pressure' in SE Asia
-
EU, Canada to build 'new chapter' in alliance at Montreal summit
-
Blue Laser Fusion Announces Successful Closing of Capital Raise and Alternative Public Offering to Accelerate Directed-Energy Defense and Fusion Energy Commercialization
-
Ur-Energy Announces 120-Hole Drill Program to Unlock Growth Potential at Lost Creek South, Wyoming
-
Hillcrest Energy Technologies to Present at Market Bridge Live in London
-
Trifecta Gold Announces Drill Results from Rye Project, Yukon
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - October 29
-
Guardian Metal Resources PLC Announces Investor Presentation
-
Tocvan Pilot Mine Trench at Gran Pilar Averages 4.6 g/t Au With Samples Up to 24.4 g/t Au; New Zone 1.3 km East Returns Up to 234 g/t Ag
-
Wealthy.ai Premium Domain Offered for Strategic Acquisition as AI Reshapes Wealth Management
-
Storm Preparedness: The Equipment Worth Investing In
-
No penalty practice? No problem for Man City in shoot-out win
-
Argentine football fan jailed for threats over Di Maria return
-
Microsoft beats expectations fueled by Azure cloud business
-
Liverpool beat Chelsea in League Cup shoot-out, Man City survive scare
-
Chelsea win as Bayern draw with Madrid in Women's Champions League
-
Inter leave it late again in Serie A as AC Milan, Juventus lose
-
Kane watches as Bayern cruise into German Cup last 16
Drugmaker asks US Supreme Court to restore abortion pill access
A key manufacturer of the United States' most widely used abortion pill asked the Supreme Court on Saturday to restore access to the drug, a day after a lower court halted mail delivery of the medication.
Mifepristone, which prevents pregnancy progression, is used alongside misoprostol, which empties the uterus, in the majority of abortions in the United States. It is approved for use up to 10 weeks into a pregnancy.
Danco Laboratories, which manufactures mifepristone and is one of two companies distributing the drug in the United States, asked the top court to stay a Friday decision by the Fifth Circuit Court of Appeals that temporarily blocked abortion providers from prescribing and shipping the drug nationwide.
The lower court ordered that women seeking abortions anywhere in the United States had to obtain mifepristone at a clinic, rather than by mail order or through a pharmacy.
That decision, "injects immediate confusion and upheaval into highly time-sensitive medical decisions," the drugmaker wrote in its filing with the Supreme Court.
"The resulting chaos for patients, providers, pharmacies, and the drug-regulatory system is a quintessential irreparable harm that underscores the need for emergency relief from this Court."
Mifepristone has been approved since 2000 and is also routinely used for managing early miscarriages.
Anti-abortion activists, however, have called the drug's safety into question, with some citing a study conducted by a conservative think tank that never underwent formal peer review.
In 2024, the Supreme Court rejected a bid to restrict the drug, ruling that anti-abortion groups and doctors calling for greater limits lacked legal standing to bring the case.
Since a 2022 Supreme Court decision that struck down a nationwide right to abortion, some 20 states have banned or restricted it.
Polls show a majority of Americans support legal access to abortion even as activists push to limit or ban it outright.
P.Stevenson--AMWN